Jonathan Cebon

44.9k total citations · 4 hit papers
278 papers, 13.6k citations indexed

About

Jonathan Cebon is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Jonathan Cebon has authored 278 papers receiving a total of 13.6k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Oncology, 141 papers in Immunology and 116 papers in Molecular Biology. Recurrent topics in Jonathan Cebon's work include Immunotherapy and Immune Responses (115 papers), CAR-T cell therapy research (55 papers) and Cancer Immunotherapy and Biomarkers (43 papers). Jonathan Cebon is often cited by papers focused on Immunotherapy and Immune Responses (115 papers), CAR-T cell therapy research (55 papers) and Cancer Immunotherapy and Biomarkers (43 papers). Jonathan Cebon collaborates with scholars based in Australia, United States and Belgium. Jonathan Cebon's co-authors include Ian D. Davis, Eugene Maraskovsky, Andreas Behren, Graham J. Lieschke, Weisan Chen, Thomas Luft, George Morstyn, Tracey Toy, Darryl Maher and Judith E. Layton and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Jonathan Cebon

275 papers receiving 13.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

2017 1.1k citations Jonathan Cebon et al. profile →
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

2000 936 citations Jonathan Cebon et al. profile →
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology.

1994 678 citations Jonathan Cebon et al. profile →
A gut microbial signature for combination immune checkpoint blockade across cancer types

2024 67 citations Oliver Klein, Ben Markman et al. profile →

Peers

Countries citing papers authored by Jonathan Cebon

Since Specialization

Citations

This map shows the geographic impact of Jonathan Cebon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Cebon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Cebon more than expected).

Fields of papers citing papers by Jonathan Cebon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Cebon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Cebon. The network helps show where Jonathan Cebon may publish in the future.

Co-authorship network of co-authors of Jonathan Cebon

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Cebon. A scholar is included among the top collaborators of Jonathan Cebon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Cebon. Jonathan Cebon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial 2024 ·Annals of Oncology ·Oliver Klein, Matteo S. Carlino, (unknown), Craig Underhill, Jimmy Bok Yan So, Damien Kee, Yoland Antill, (unknown), Henry Chan, Rosemary Harrup, (unknown), Jamie Palmer, Dawn Thomas, (unknown), Jonathan Cebon, Bo Gao	5
2	Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma 2020 ·Science Advances ·Jing Wang, Alain Wuethrich, Abu Ali Ibn Sina, Rebecca E. Lane, Lynlee L. Lin, Yuling Wang, Jonathan Cebon, Andreas Behren, Matt Trau	131
3	Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma 2020 ·Cancer Immunology Research ·Pouya Faridi, Katherine Woods, Simone Ostrouska, (unknown), (unknown), (unknown), Stephen Q. Wong, Weisan Chen, Sri H. Ramarathinam, Terry C.C. Lim Kam Sian, Nathan P. Croft, Chen Li, Rochelle Ayala, Jonathan Cebon, Anthony W. Purcell, Ralf B. Schittenhelm, Andreas Behren	41
4	Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers 2020 ·Clinical Cancer Research ·Oliver Klein, Damien Kee, Ben Markman, Michael Michael, Craig Underhill, Matteo S. Carlino, Louise Jackett, Caroline Lum, Clare L. Scott, Adnan Nagrial, Andreas Behren, (unknown), Jodie Palmer, Jonathan Cebon	116
5	BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival 2019 ·Cell Death and Disease ·Erinna F. Lee, Tiffany J. Harris, Sharon Tran, Marco Evangelista, Surein Arulananda, Thomas John, (unknown), (unknown), Haoran Zhu, Gency Gunasingh, David Segal, Andreas Behren, Jonathan Cebon, Alexander Dobrovic, John M. Mariadason, Andreas Strasser, Leona Rohrbeck, Nikolas K. Haass, Marco J. Herold, W. Douglas Fairlie	142
6	Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel 2019 ·Journal of Molecular Diagnostics ·Elin S. Gray, (unknown), Michelle R. Pereira, Leslie Calapre, (unknown), Darryl Irwin, Brett Chapman, Muhammad A. Khattak, Jeanette Raleigh, Athena Hatzimihalis, Jonathan Cebon, Shahneen Sandhu, Grant A. McArthur, Michael Millward, Mel Ziman, Alexander Dobrovic, Stephen Q. Wong	18
7	A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response 2019 ·Journal of Investigative Dermatology ·Heloise M. Halse, Franco Caramia, Catriona McLean, Minyu Wang, Han Xian Aw Yeang, Simon P. Keam, Andreas Behren, (unknown), Martin Haskett, Jonathan Cebon, Grant A. McArthur, Paul J. Neeson, Victoria Mar	8
8	Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma 2018 ·Scientific Reports ·Heloise M. Halse, Andrew J. Colebatch, Pasquale Petrone, Melissa A. Henderson, Jane K. Mills, Hayden Snow, Jennifer A. Westwood, Shahneen Sandhu, Jeanette Raleigh, Andreas Behren, Jonathan Cebon, Phillip K. Darcy, Michael H. Kershaw, Grant A. McArthur, David Gyorki, Paul J. Neeson	74
9	Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity 2016 ·Cancer Immunology Research ·Jun Yao, Otávia L. Caballero, Ying Huang, Calvin Lin, Donata Rimoldi, Andreas Behren, Jonathan Cebon, Mien‐Chie Hung, John N. Weinstein, Robert L. Strausberg, Qi Zhao	49
10	Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma 2015 ·Clinical Cancer Research ·Miles C. Andrews, Natalie Turner, (unknown), Andrew W. Roberts, Andrew Grigg, Andreas Behren, Jonathan Cebon	3
11	Optimal Effector Functions in Human Natural Killer Cells Rely upon Autocrine Bone Morphogenetic Protein Signaling 2014 ·Cancer Research ·Neil C. Robson, Laura Hidalgo, (unknown), Heng Wei, Víctor G. Martínez, (unknown), Gustavo J. Melen, Andrew S. MacDonald, Alexander Phythian‐Adams, Rosa Sacedón, Eugene Maraskovsky, Jonathan Cebon, Manuel Ramı́rez, Ángeles Vicente, Alberto Varas	21
12	MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells 2014 ·Cancer Immunology Research ·Laura J. Vella, Anupama Pasam, Nektaria Dimopoulos, Miles C. Andrews, Ashley Knights, (unknown), Jamila Louahed, Weisan Chen, Katherine Woods, Jonathan Cebon	116
13	Tumor-Specific T-cell Help Is Associated with Improved Survival in Melanoma 2013 ·Clinical Cancer Research ·Katherine Woods, Jonathan Cebon	12
14	BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage 2013 ·Clinical Cancer Research ·Victoria Mar, Stephen Q. Wong, Jason Li, Richard A. Scolyer, Catriona McLean, Anthony T. Papenfuss, Richard W. Tothill, Hojabr Kakavand, Graham J. Mann, John F. Thompson, Andreas Behren, Jonathan Cebon, Rory Wolfe, John W. Kelly, Alexander Dobrovic, Grant A. McArthur	100
15	Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial 2009 ·Clinical Cancer Research ·Ian D. Davis, (unknown), Richard Kefford, Michael Millward, Jonathan Cebon, Birte K. Skrumsager, Ulrik Mouritzen, Lasse Tengbjerg Hansen, Kresten Skak, Dorthe Lundsgaard, Klaus Stensgaard Frederiksen, Paul E.G. Kristjansen, Grant A. McArthur	120
16	Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma 2008 ·Clinical Cancer Research ·Thomas John, Michael A. Black, Tumi Toro, (unknown), Craig Gedye, Ian D. Davis, Parry Guilford, Jonathan Cebon	44
17	The Regulatory T Cell–Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells 2008 ·Cancer Research ·Lisa M. Ebert, Bee Shin Tan, Judy Browning, Suzanne Svobodová, Sarah E. Russell, (unknown), Craig Gedye, Denis J. Moss, Sweet Ping Ng, Duncan MacGregor, Ian D. Davis, Jonathan Cebon, Weisan Chen	152
18	An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma 2007 ·Clinical Cancer Research ·Ian D. Davis, Birte K. Skrumsager, Jonathan Cebon, Theo Nicholaou, John Barlow, Niels Peter Hundahl Møller, Kresten Skak, Dorthe Lundsgaard, Klaus Stensgaard Frederiksen, Peter Thygesen, Grant A. McArthur	132
19	Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells 2003 ·Blood ·Max Schnurr, Tracey Toy, Amanda Shin, Gunther Hartmann, Simon Rothenfußer, (unknown), Ian D. Davis, Jonathan Cebon, Eugene Maraskovsky	150
20	Monoclonal Antibodies that Recognize Human Granulocyte-Macrophage Colony-Stimulating Factor and Neutralize Its Bioactivity In Vitro 1990 ·Hybridoma ·Peter J. Dempsey, Judith E. Layton, Ulrich Dührsen, Nicos A. Nicola, Jonathan Cebon, Antony W. Burgess, George Morstyn	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact